Fortunately, HBV is preventable through hepatitis B vaccination. The vaccine has been shown to be safe and efficacious for newborns and children [6,7]. Countries which have implemented universal newborn HBV vaccination have reported substantial declines in HBV incidence that is associated with these increases in vaccination coverage [8,9]. Thus, most cases of HBV and its sequelae could be prevented by a universal newborn HBV vaccination program. The success of such public health initiatives depends largely on the degree to which health care providers promote vaccination.

Despite the availability of free vaccine for newborns in Georgia, anecdotal information suggested that health care worker (HCW) concerns about the safety of the HBV vaccine posed an important challenge to universal vaccine coverage for newborns [10]. The study conducted among 297 HCWs reported that only 54% of study participants would recommend the vaccine to other HCWs. Perception of vaccine safety was identified as the most important predictor for acceptance (Prevalence Ratio (PR)=3.25 [95% CI:1.19, 8.90]) and for willingness to recommend HBV vaccine to their colleagues [11].

While neonatologists and pediatricians are responsible for newborn HBV vaccinations, HCWs of other specialties likely have a significant indirect impact on vaccine coverage in the general population. Georgians, like those of every culture, also seek advice for health-related decisions from relatives or friends, some of whom may be physicians and nurses. This form of education may supersede the advice of physicians who are known only through a transient patient-provider relationship. Thus, the casual dialogue about HBV vaccination shared by HCWs among acquaintances, friends and family, and accordingly, their willingness to advise vaccination, may affect HBV vaccination coverage among the most vulnerable population—newborns.

Overall, 478 (36%) study participants reported recommending against HBV vaccination for children. Of the 279 who reported a specific reason, the most common was concern about an adverse vaccine event (38%, 111/279) followed by belief that the vaccine was not effective (23%, 64/279).

Based on the bivariate analysis, the strongest correlate for likelihood of recommending HBV vaccination was the HCW’s own vaccination status. Unvaccinated HCWs were much more likely to recommend against HBV vaccine than their vaccinated colleagues (40.40% vs 11.40%, respectively, prevalence ratio (PR) = 3.54; 95% CI: 2.38, 5.29). Age was also a factor, with older HCWs more likely to recommend against HBV vaccine compared to those younger than age 35 (39.20% vs 28.40%, respectively). There was no substantive difference between the recommendations for physicians compared to nurses. A third of paediatricians recommended against HBV vaccine, similar to other HCWs. Dialysis HCWs were the most likely to recommend vaccination, with only 10.9% (PR=3.03; 95% CI: 1.58, 5.85) recommending against it. By multivariate analysis, the only significant predictor of recommending HBV vaccine for newborns was the HCW’s own vaccination status (Table ​(Table11).

This study found that 36% of HCWs did not recommend HBV vaccination for newborns. Only two groups of HCWs appeared to be importantly different: dialysis workers who see the impact of HBV among their patients at very high risk of the infection, and HCWs who are vaccinated against HBV. However, as evidence of the intractable nature of vaccine safety concerns, one in every ten of these HCWs would also recommend against HBV vaccine for newborns. Age correlated with vaccine status, with older HCWs being the least likely to be vaccinated and least likely to recommend vaccine. These findings provide insight into the demographics of concern about vaccine safety and inform the development of potential interventions to improve knowledge about HBV vaccination.

There was no statistically significant difference in the prevalence of anti-HBc in vaccinated and unvaccinated persons. This could be probably explained by the fact that during the HCW’s HBV vaccination campaign in 2001 there was no HBV antibody testing conducted prior to HBV vaccination and those being already HBV infected without knowing it received the vaccine.

During the study period over 80% of HCWs were not yet vaccinated against HBV. While this finding is similar to many developing countries [18-20], it is the polar opposite of most developed countries where the majority of HCWs are vaccinated [21-24]. These unvaccinated HCWs are substantially less likely to recommend vaccine to newborns. Fear of adverse events and lack of knowledge regarding vaccine efficacy are major factors affecting many HCWs recommendations and personal health practices. While these issues may be addressed by educational programs, the specific experiences of this population suggest educational programs alone are insufficient. Targeted programs which specifically address the publicized event and shed light on the facts may help assuage some concerns.

Personal experience with HBV vaccine appears to be associated with recommending vaccine to newborns.

Having received HBV vaccine is associated with a healthcare worker recommending the vaccine to newborns. The reasons a healthcare worker might receive the vaccine may be complex. Yet access to the vaccine may be a key factor. If the vaccine is available to the HCW and the barrier of cost is removed, it seems likely that the HCW may consider the personal cost-benefit relationship in a different context. They ultimately may see the benefits of the vaccine as more favourable, receive the vaccine and ultimately be more likely to recommend HBV vaccination for newborns as well as others.

Vaccination programs for HCWs can be justified based on their occupational risk of infection. Cost is always a factor in any vaccine initiative. Some hospitals in a neighbouring country, Turkey, have screened HCWs upon employment and identified those susceptible to HBV for vaccination. This screening and vaccine program is cost-effective given the relatively large proportion of HCWs that have already been exposed to HBV. In Georgia, approximately 30% of HCWs have evidence of prior HBV exposure and thus would not directly benefit from the vaccine. The remaining HCWs would benefit from the vaccine and safety data suggests that those HCWs who were already vaccinated would not be harmed by revaccination (essentially an additional booster) [25,26]. This last point is important because one significant barrier to a screening program is the potential harm caused by employers identifying HCWs who are infectious. Thus, creating an accessible national program for HCW vaccination must rely on a confidential screening program, or universal vaccination for those with an unreliable vaccination history.

Cost-effectiveness studies on HBV vaccine programs for HCWs typically focus on the occupational risks of HBV infection and benefit of the vaccine to protect HCWs and patients [27,28]. This study suggests increasing the proportion of HCWs vaccinated for HBV may increase vaccination coverage of newborns and children.

This study had a strong sampling design and benefited from laboratory testing to establish exposure to HBV. Like all studies, it also had limitations. The primary limitation is that all other information was self-reported. Based on the results, there does not appear to be substantial bias due to social desirability as the proportion of HCWs recommending vaccine is relatively low. Another limitation is that participation was not 100%. It is possible that HCWs with active disease were more likely to refuse participation. However, this would not alter the overall conclusions.

The prevalence of HBV infection (anti-HBc) among study participants was about 29%, higher than the prevalence among the general population in Georgia (20%) [29]. This difference could be explained by the occupational exposure to HBV among HCWs. Even if the majority of HCWs are not likely to develop significant liver disease sequelae if infected later in life, they can transmit the virus to patients and household members who have not been vaccinated. Thus, it would be useful to assess cost-effectiveness of screening for both HBV antibodies prior to vaccinating susceptibles and universal vaccination for HCWs in the absence of screening. In either case, cost-effectiveness analyses of HBV vaccination programs for HCWs should broaden their assessment of benefits.

In 2009 the Ministry of Labour, Health, and Social Affairs of Georgia and the National Center for Diseases Control established a hepatitis B catch-up vaccination program for at-risk healthcare workers, medical students, and adolescents in three regions of the country: Tbilisi (capital city with 1/3 of Georgia population), Imereti and Adjara (regions in western Georgia) with support of Rostropovich-Vishnevskaya Foundation.

By 2010, 12,963 health care workers have been screened for hepatitis B (Anti-HBc) and 4,579 (35.3%) appeared to be Anti-HBc(+). The rest of HCWs were offered administration of HBV vaccine on a voluntary basis, from which 7,000 have been vaccinated against hepatitis B.